Clinical Care Options in collaboration with the National Eczema Association is hosting an innovative and engaging symposium IL-13 Inhibition in Moderate to Severe Atopic Dermatitis: A Clinical Skills ...
Dupilumab in atopic dermatitis treatment had the most favorable cardiometabolic safety profile when compared with methotrexate and cyclosporine.
Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo ...
The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the ...
Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...
A new medicine, Nenolizumab, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat two skin conditions ...
Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedi ...
An AI-enabled wearable sensor with vibratory feedback significantly reduces nocturnal scratching in atopic dermatitis, ...
Discover a study where findings revealed that using the new device significantly decreased both total and hourly scratch ...
UK MHRA grants marketing approval to Galderma’s nemolizumab to treat prurigo nodularis and atopic dermatitis: United Kingdom Tuesday, February 18, 2025, 14:00 Hrs [IST] The Medi ...
Astria advances innovative therapies for hereditary angioedema and atopic dermatitis. Strong cash position supports pivotal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback